CRA’s Life Sciences Practice team recently analyzed past predictions of industry trends and compared them to what has occurred in the past decade, identified influencing factors and success drivers of these trends, and applied them to current industry predictions to outline what needs to occur for them to come to fruition in the years ahead.
In their analysis they divided past predictions into three main categories: trends that were accurately predicted, trends that were off-target, and trends that were not broadly predicted but occurred. Among the accurately predicted trends were the rise of new and innovative therapies for rare and orphan diseases and increased interest in development of genomic analysis and DNA sequencing technologies.
Predictions that were off target included the potential of personalized medicines to transform research and drug development in a wide range of indications. Although there has been progress in the development of personalized medicines, it has been limited mostly to drugs in oncology and has not had the expected impact in other therapeutic areas nor has it resulted in widespread diagnostics, safer dosing options, or tailored patient and physician support.
